This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Neurofilament light chain (NfL) and peripheral neuropathy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Measurement of neurofilament light chain and peripheral neuropathy

Neurofilaments are the major cytoskeletal proteins of neurons in both the CNS and peripheral nervous system and form a lattice comprising neurofilament light (NfL), medium, and heavy (NfH) chains

  • NfL
    • is a cytoskeleton protein expressed in large calibre myelinated axons
    • has a functional role in axonal growth and stability and a high expression in neuronal tissue
    • neuroaxonal damage in peripheral nerves results in the release of NfLthe extracellular space and peripheral blood, depending on the extent of damage

  • has been shown that neurofilament light chain (NfL) concentration is elevated in patients with Charcot-Marie-Tooth disease (CMT) (1)

  • monitoring of sNfL during chemotherapy can indicate ongoing neuroaxonal injury and the severity of oxaliplatin-induced peripheral neuropathy (OIPN) (2)

  • a systematic review and meta-analysis concluded that blood-based measure of neurofilament light chain may be a useful indicator of neuronal injury in patients with peripheral neuropathy (3)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.